Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Neoplasms × Pemetrexed × Clear all

Phase

Phase 1 24 Phase 2 18 Phase 3 8 Phase 1/2 6 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11 Lung Neoplasms 5 NSCLC 2 Mesothelioma 2 Recurrence 1 Nonsquamous Non-small Cell Lung Cancer 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 3 Standard of Care 3 Oxaliplatin 3 Melatonin 3 Gemcitabine 3 Fluorouracil 3 Drug Therapy 3 Capecitabine 3 gamma-Globulins 2 cobimetinib 2 Water 2 Vemurafenib 2 Sirolimus 2 Saline Solution 2 Methylphenidate 2 Lidocaine 2 Leucovorin 2 Immunoglobulins, Intravenous 2 Docetaxel 2 Ciprofloxacin 2 valrubicin 1 trametinib 1 sotrovimab 1 sintilimab 1 relatlimab 1 racemetyrosine 1 pertuzumab 1 pembrolizumab 1 osimertinib 1 netupitant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02777788 2017-10-10

TCM

Shanghai University of Traditional Chinese Medicine

Phase 2/3 Unknown

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡